Effects of transfusion of leucocyte-depleted erythrocytes in cardiac valve surgey on postoperative complications

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN68522192

Enrollment

496

Registered

2005-12-20

Start date

1999-05-01

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart surgery Surgery Heart surgery

Interventions

Randomisation to receive buffy-coat-depleted (PC) or leukocyte-depleted transfusions when necessary. Pre-operative, at arrival at Intensive Care Unit (ICU) and day 1 postoperatively at ICU blood sampl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing valve surgery (+/- Coronary Artery Bypass Grafting [CABG]).

Exclusion criteria

Exclusion criteria: 1. Patients under 18 years of age 2. Medical indications for leucocyte-depleted erythrocytes 3. Received blood transfusions within previous 3 months

Design outcomes

Primary

Measure	Time frame
90-days mortality and causes of deaths.	—

Secondary

Measure	Time frame
1. In-hospital mortality 2. 30- and 60-days mortality 3. Onset and type of postoperative infections 4. Onset and type of MODS 5. ICU-stay, hospital-stay and long-term survival 6. Pro-and anti-inflammatory cytokine profile, complement system activation and inflammatory mediators 7. Cost-effective-analysis for the primary outcome	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026